Mitsubishi Chemical has agreed to sell its pharmaceutical subsidiary, Mitsubishi Tanabe Pharma, to US private equity firm Bain Capital in a deal valued at JPY510bn ($3.36bn) as part of a broader effort to streamline its portfolio.
The sale comes amid a surge in private equity-led buyouts in Japan, as companies divest non-core assets to enhance corporate and shareholder value. Foreign funds like Bain have significantly increased their acquisitions in Japan, pushing inbound mergers and acquisitions (M&A) in the country to the top of Asia’s leaderboard in 2024 — the first time since 1999.
According to data from LSEG, the total value of inbound deals in Japan reached $85.5bn in 2024, a rise of over 600% compared to the previous year. This figure includes a $47bn takeover bid for Seven & i Holdings by Canadian retailer Alimentation Couche-Tard.
Mitsubishi Tanabe Pharma became a subsidiary of Mitsubishi Chemical in 2020, aiming to create synergies between the two entities. However, Mitsubishi Chemical noted that “changes in the industry and business structure have reduced the potential for synergies.”
The company also highlighted that substantial investment would be required to enhance Mitsubishi Tanabe Pharma’s research and development capabilities and drive further growth — an undertaking deemed unfeasible under its ownership.
